Esperion Therapeutics, Inc. (ESPR) Posts Quarterly Earnings Results, Misses Estimates By $0.25 EPS
Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by $0.25, Briefing.com reports. During the same quarter last year, the firm posted ($0.62) earnings per share.
Esperion Therapeutics (NASDAQ ESPR) opened at 52.13 on Wednesday. The firm’s market cap is $1.18 billion. The firm’s 50-day moving average price is $45.38 and its 200 day moving average price is $33.91. Esperion Therapeutics has a 52-week low of $9.40 and a 52-week high of $57.38.
ESPR has been the subject of several recent research reports. Zacks Investment Research cut Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. ValuEngine raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Citigroup Inc. reissued a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 22nd. Deutsche Bank AG started coverage on Esperion Therapeutics in a research report on Friday, June 23rd. They set a “buy” rating and a $48.00 target price on the stock. Finally, BidaskClub raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, June 25th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $39.16.
A number of hedge funds have recently bought and sold shares of the stock. Ameriprise Financial Inc. acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $1,498,000. UBS Asset Management Americas Inc. acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $6,608,000. Pictet Asset Management Ltd. acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $4,539,000. Bank of New York Mellon Corp boosted its stake in Esperion Therapeutics by 29.4% in the first quarter. Bank of New York Mellon Corp now owns 104,603 shares of the biopharmaceutical company’s stock valued at $3,693,000 after buying an additional 23,740 shares in the last quarter. Finally, Princeton Alpha Management LP acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $205,000. Hedge funds and other institutional investors own 85.20% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.